RA’s acquisition expands UCB’s neuromuscular portfolio
17/10/19 -"UCB has broadened its neuromuscular portfolio with the €2.2bn acquisition of RA pharmaceuticals – blockbuster potential drug, Zilucoplan (expected launch in 2023), is RA’s key drug which complements ..."
Pages
52
Language
English
Published on
17/10/19
You may also be interested by these reports :
13/05/24
Lundbeck’s 2023 profitability fell short of our expectations as, despite some yoy improvement, margins were under pressure from higher SG&A related ...
10/05/24
Novonesis reported largely in-line Q1 24 numbers. Q1 24 revenue was up 45% on a pro-forma basis, helped by strong performances in the key segments of ...
08/05/24
Sandoz is moving ahead well with two crucial aspects of its medium-term sales and profitability goals: 1/ a strong performance from Biosimilars and ...
07/05/24
Q1 sales missed the consensus estimates, although the CER growth was largely in line with the firm’s full-year outlook. Biosimilars were the main ...